藍帆醫療(002382.SZ)：夯實產業根基積極佈局高附加值醫療護理業務
醫用防護用品不斷激增的訂單，讓藍帆醫療(002382.SZ)在護理業務上賺的盆滿缽滿，公司也順勢而為，不斷加大護理事業的業務版圖，領先同業的建設速度，讓公司駛向發展快車道。
2021年5月13日，藍帆醫療在中國國際醫療器械展覽會(下稱"CMEF")上推出兩款家庭應急包產品。據公司相關負責人表示："開發家庭應急包的初衷是響應國家發改委提出的家庭應急物資儲備清單建議，滿足家庭應急物資儲備需求。新品主要特點體現在優選材料、模塊結構設計、夜光指示等。"
同時，藍帆醫療護理事業部還將推出健康防護系列組合，如口罩、棉籤、棉球、紗布等醫用敷料產品，完成戰略規劃中家庭健康防護產品手部防護、呼吸防護、創傷護理、日常防護四大系列，成為家庭健康防護一體化解決方案提供者。
2020年7月24日，藍帆醫療收購武漢必凱爾，正式佈局醫療急救護理產業；12月16日，與湖北省團風縣人民政府簽署戰略合作協議，投資8億元建設藍帆醫療護理事業部總部、應急防護產業園等項目；2021年1月30日，項目正式啟動建設，展現了藍帆速度。
目前護理事業部正逐步形成急救包、護理包、防疫包組合，醫用耗材及敷料，無紡布基礎材料的產業鏈條佈局。其中醫用耗材及敷料包括應急傷口護理類：紗布、止血繃帶，敷料貼、棉籤等。個人防護和消殺類：消毒濕巾、口罩、防護服、隔離服等。
除護理業務外，公司的防護用品也對2020年度業績的增長提供了有力的支撐，報吿期內公司健康防護產品實現收入68.31億元，實現淨利潤32.18億元。疫情也結構性地提升了各個國家、社會、機構對健康防護的意識與理念，並開始完善應急能力體系。
公司健康防護領域在醫療及防護手套、急救包、醫用敷料等醫療防護產品線的基礎上，緊急啟動面罩、護目鏡、防護眼鏡、條帽、KN95口罩、無紡布隔離衣、CPE隔離衣等防疫物資的全球貿易行動。
此外，公司子公司武漢必凱爾還在急救箱包為主的各類緊急救援產品和一次性健康防護用品領域嶄露頭角，是特斯拉所有車型車載急救包全球供應商，與德國奔馳、寶馬、奧迪、法國雷諾等車企形成了長期戰略合作，競爭優勢明顯。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
